Expansions of tumor-reactive Vdelta1 gamma-delta T cells in
newly diagnosed patients with chronic myeloid leukemia

J 2023

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

KNIGHT, Andrea, Martin PISKÁČEK, Michal JURAJDA, Jiřina PROCHÁZKOVÁ, Zdeněk RÁČIL et. al.

Základní údaje

Originální název

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

Autoři

KNIGHT, Andrea (203 Česká republika, garant, domácí), Martin PISKÁČEK (40 Rakousko, domácí), Michal JURAJDA (203 Česká republika, domácí), Jiřina PROCHÁZKOVÁ (203 Česká republika, domácí), Zdeněk RÁČIL (203 Česká republika), Daniela ŽÁČKOVÁ (203 Česká republika, domácí) a Jiří MAYER (203 Česká republika, domácí)

Vydání

Cancer immunology, immunotherapy, NEW YORK, SPRINGER, 2023, 0340-7004

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.800 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130077

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s00262-022-03312-3

UT WoS

000884524700001

Klíčová slova anglicky

Gamma-delta T cells; Chronic myeloid leukemia; Tumor immunotherapy; Clonality

Štítky

14110212, 14110518, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 1. 2024 10:20, Mgr. Tereza Miškechová

Anotace

V originále

Recent studies have underscored the importance of gamma-delta (γδ) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we analyzed Vδ1 and Vδ2 γδ T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients (n = 40) who had initiated tyrosine kinase inhibitor (TKI) therapy including imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4). Patient peripheral blood samples were analyzed at diagnosis and monitored prospectively at 3, 6, 12 and 18 months post-TKI. γδ T cells isolated from healthy donors and CML patients were used against K562, LAMA-84 and KYO-1 cell lines and against primary CML cells in cytotoxicity assays. We found large expansions of Vδ1 and Vδ2 T cells in patients at diagnosis compared to age-matched healthy donors (n = 40) (p < 0.0001). The γδ T cell reconstitution in patients on imatinib and also on nilotinib showed significant reductions of Vδ1 T cell and Vδ2 T cell absolute counts at 3 months compared to diagnosis. Importantly, Vδ1 and Vδ2 T absolute cell counts remained at normal levels from 3 months throughout the follow-up. Next, we observed susceptibility to specific lysis of primary CML tumor cells by Vδ1 T cells from healthy donors. Furthermore, we determined inherent cytotoxic reactivity by autologous patients’ Vδ1 T lymphocytes against primary CML tumor cells. Finally, the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI. Our results provide further evidence into γδ T cell antileukemia immunity in CML that might be beneficial for long-term disease control and treatment outcome.

Návaznosti

NV19-05-00410, projekt VaV

Název: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme

Investor: Ministerstvo zdravotnictví ČR, Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme

Citovat

KNIGHT, Andrea, Martin PISKÁČEK, Michal JURAJDA, Jiřina PROCHÁZKOVÁ, Zdeněk RÁČIL, Daniela ŽÁČKOVÁ a Jiří MAYER. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia. Cancer immunology, immunotherapy. NEW YORK: SPRINGER, 2023, roč. 72, č. 5, s. 1209-1224. ISSN 0340-7004. Dostupné z: https://dx.doi.org/10.1007/s00262-022-03312-3.

@article{2233738,
   author = {Knight, Andrea and Piskáček, Martin and Jurajda, Michal and Procházková, Jiřina and Ráčil, Zdeněk and Žáčková, Daniela and Mayer, Jiří},
   article_location = {NEW YORK},
   article_number = {5},
   doi = {http://dx.doi.org/10.1007/s00262-022-03312-3},
   keywords = {Gamma-delta T cells; Chronic myeloid leukemia; Tumor immunotherapy; Clonality},
   language = {eng},
   issn = {0340-7004},
   journal = {Cancer immunology, immunotherapy},
   title = {Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia},
   url = {https://link.springer.com/article/10.1007/s00262-022-03312-3},
   volume = {72},
   year = {2023}
}

TY  - JOUR
ID  - 2233738
AU  - Knight, Andrea - Piskáček, Martin - Jurajda, Michal - Procházková, Jiřina - Ráčil, Zdeněk - Žáčková, Daniela - Mayer, Jiří
PY  - 2023
TI  - Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia
JF  - Cancer immunology, immunotherapy
VL  - 72
IS  - 5
SP  - 1209-1224
EP  - 1209-1224
PB  - SPRINGER
SN  - 03407004
KW  - Gamma-delta T cells
KW  - Chronic myeloid leukemia
KW  - Tumor immunotherapy
KW  - Clonality
UR  - https://link.springer.com/article/10.1007/s00262-022-03312-3
N2  - Recent studies have underscored the importance of gamma-delta (γδ) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we analyzed Vδ1 and Vδ2 γδ T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients (n = 40) who had initiated tyrosine kinase inhibitor (TKI) therapy including imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4). Patient peripheral blood samples were analyzed at diagnosis and monitored prospectively at 3, 6, 12 and 18 months post-TKI. γδ T cells isolated from healthy donors and CML patients were used against K562, LAMA-84 and KYO-1 cell lines and against primary CML cells in cytotoxicity assays. We found large expansions of Vδ1 and Vδ2 T cells in patients at diagnosis compared to age-matched healthy donors (n = 40) (p < 0.0001). The γδ T cell reconstitution in patients on imatinib and also on nilotinib showed significant reductions of Vδ1 T cell and Vδ2 T cell absolute counts at 3 months compared to diagnosis. Importantly, Vδ1 and Vδ2 T absolute cell counts remained at normal levels from 3 months throughout the follow-up. Next, we observed susceptibility to specific lysis of primary CML tumor cells by Vδ1 T cells from healthy donors. Furthermore, we determined inherent cytotoxic reactivity by autologous patients’ Vδ1 T lymphocytes against primary CML tumor cells. Finally, the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI. Our results provide further evidence into γδ T cell antileukemia immunity in CML that might be beneficial for long-term disease control and treatment outcome.
ER  -

KNIGHT, Andrea, Martin PISKÁČEK, Michal JURAJDA, Jiřina PROCHÁZKOVÁ, Zdeněk RÁČIL, Daniela ŽÁČKOVÁ a Jiří MAYER. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia. \textit{Cancer immunology, immunotherapy}. NEW YORK: SPRINGER, 2023, roč.~72, č.~5, s.~1209-1224. ISSN~0340-7004. Dostupné z: https://dx.doi.org/10.1007/s00262-022-03312-3.

Podrobný výpis o publikaci